New Drugs 2011-2012- Pharmacist
The FDA was busy approving 35 new drugs during 2011, the second highest number approved in 10 years. This issue provides detailed reviews of the new drugs most likely to be encountered in the outpatient or community practice setting. These include fidaxomicin (DificidTM), an important drug for Clostridium difficile infection; spinosad (NatrobaTM), an improved treatment for head lice; indacaterol (ArcaptaTM, NeohalerTM) and roflumilast (Daliresp®), 2 drugs for COPD; and ticagrelor (BrilintaTM), a new antiplatelet agent. The second warfarin alternative to reach the market, rivaroxaban (Xarelto®), is also reviewed. It is approved for stroke prevention in patients with atrial fibrillation, and deep vein thrombosis (DVT) prevention in patients having hip or knee replacement. New indications are discussed for 3 commonly used drugs: gabapentin enacarbil ER (Horizant®), tadalafil (Cialis®), and zolpidem sublingual (Intermezzo®). Two new drugs for hepatitis C that are major breakthroughs in therapy, boceprevir (VictrelisTM) and telaprevir (IncivekTM), and an important 3-drug combination for HIV infection, rilpirivine (EdurantTM) were covered previously in The Rx Consultant (November, 2011 and February 2012, respectively). Useful tables summarize the key points of the new drugs and products. Throughout the issue practical patient counseling points are highlighted separately for easy access.